Latest News of CCCC
New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)
Analysts upgraded C4 Therapeutics' revenue forecasts, predicting a 3.1% decline in sales in 2024. Despite reduced losses and improved revenue outlook, the consensus price target fell 14%. The company ...
C4 Therapeutics, Inc. (CCCC): Is This the Best Biotech Penny Stock to Buy Now?
The article discusses the potential of biotech penny stocks in 2024, focusing on C4 Therapeutics, Inc. as a promising investment. With a strong financial position and strategic partnerships, C4 Therap...
CCCC Design & Consulting Group And Two More Top Dividend Stocks In China
China's market struggles with declining home prices and mixed economic signals, impacting investor sentiment. Dividend stocks like CCCC Design & Consulting Group offer potential stability and income i...
-
It Looks Like C4 Therapeutics, Inc.'s (NASDAQ:CCCC) CEO May Expect Their Salary To Be Put Under The Microscope
By Yahoo! Finance | 5 months agoC4 Therapeutics' disappointing 87% shareholder loss and 2.9% EPS decline over three years will likely concern investors. CEO compensation, although in line with industry standards, is being questioned...